Skip to main content
InvestorsNews

MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total knee replacement

By August 31, 2023March 15th, 2024No Comments1 min read